<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56921">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781533</url>
  </required_header>
  <id_info>
    <org_study_id>REACTbyALGO-1</org_study_id>
    <nct_id>NCT01781533</nct_id>
  </id_info>
  <brief_title>Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor</brief_title>
  <official_title>An Open, Single-centre, Non-controlled Feasibility Study Using a Software-algorithm Based Insulin Therapy to Control Blood Glucose in Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the performance of a software-algorithm based insulin therapy to control
      blood glucose in Type 1 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>the percentage of glucose values obtained every 15 min in predefined glucose ranges</measure>
    <time_frame>15 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injected insulin dose</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the glucose monitoring unit</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absolute and relative difference between glucose monitoring readings and reference values (blood glucose) will be used to determine the accuracy of the monitoring unit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>algorithm</intervention_name>
    <arm_group_label>algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 to 75 years (both inclusive)

          -  Informed consent obtained after being advised of the nature of the study

          -  The subject has Type 1 diabetes (as defined by WHO) for at least 24 months

          -  The subject's HbA1c &lt;= 10%

          -  Body Mass Index (BMI) &lt;= 35 kg/m2

          -  The subject is treated with continuous subcutaneous insulin infusion for at least 3
             month

        Exclusion Criteria:

          -  Subject is actively enrolled in another clinical trial or took part in a study within
             30 days

          -  Experienced recurrent severe hypoglycaemic unawareness

          -  Total daily insulin dose &gt;= 1.4 IU/kg

          -  Subject is using a medication that significantly impacts glucose metabolism (oral or
             topical steroids) except if stable for at least the last three months and expected to
             remain stable for the study duration

          -  Allergy against insulin Lispro

          -  A history of drug or alcohol dependence

          -  Any other significant concomitant disease such as endocrine, cardiac, neurological,
             malignant, other pancreatic disease or uncontrolled hypertension as judged by the
             investigator

          -  Uncontrolled hypertension with resting blood pressure over 140/90 mmHg

          -  Patient is pregnant, or breast feeding during the period of the study

          -  Patient donated blood in the last 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.reaction-project.eu/news.php</url>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Pieber Thomas, MD</investigator_full_name>
    <investigator_title>Univ. Prof. Dr. med.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
